Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Patel JC, Taylor SM, Juliao PC, Parobek CM, Janko M, Gonzalez LD, Ortiz L, Padilla N, Tshefu AK, Emch M, Udhayakumar V, Lindblade K, Meshnick SR. Genetic evidence of importation of drug-resistant plasmodium falciparum to Guatemala from the Democratic Republic of the Congo. Emerg Infect Dis. 2014 Jun;20(6):932-40. doi: 10.3201/eid2006.131204
Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, Greco FA. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol. 2014;19(3):479-84. doi: 10.1007/s10147-013-0583-0
McIntyre LF, Beach WR, Higgins LD, Mordin MM, Mauskopf J, Sweeney CT, Copley-Merriman C. Evidence-based medicine, appropriate-use criteria, and sports medicine: how best to develop meaningful treatment guidelines. Arthroscopy. 2013 Mar 18;29(7):1224-9.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.